Research programme: GPCR-uPAR - Science Park Raf/WilexAlternative Names: Research programme: anticancer therapeutics - Science Park Raf/Wilex; Signal transduction pathway inhibitors - Science Park Raf/Wilex
Latest Information Update: 29 Apr 2008
At a glance
- Originator Science Park Raf
- Developer Science Park Raf; Wilex
- Class Antibodies
- Mechanism of Action G protein-coupled receptor antagonists; Signal transduction pathway inhibitors; Urokinase-type plasminogen activator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Feb 2005 Preclinical trials in Cancer in Germany (Parenteral)